Sector News

Stryker posts higher profit, names new CFO

January 29, 2016
Life sciences

Medical technology company Stryker Corp (SYK.N) on Tuesday reported fourth-quarter profit slightly above analysts’ expectations on higher sales across its product lines.

The maker of artificial knee and hip implants, surgical instruments and other hospital products also announced the promotion of Glenn Boehnlein to chief financial officer, replacing William Jellison, who is retiring.

Net profit in the fourth quarter rose to $522 million, or $1.38 per share, from $260 million, or 67 cents per share, in the ear-ago period.

Excluding one-time items, Stryker said it earned $1.56 per share. Analysts on average had expected $1.55 per share, according to Thomson Reuters I/B/E/S.

Stryker previously announced fourth-quarter revenue of $2.7 billion, up 3.7 percent from a year ago.

The Kalamazoo, Mich.-based company forecast 2016 earnings in a range of $5.50 to $5.70 per share. Analysts on average were expecting $5.59 per share.

(Reporting by Susan Kelly in Chicago; Editing by Bernard Orr)

comments closed

Related News

September 17, 2022

Novo Nordisk partners with Microsoft for AI-driven drug discovery

Life sciences

Novo Nordisk has signed a new strategic partnership with Microsoft to expedite the discovery and development of drugs leveraging big data and artificial intelligence (AI). Under the deal, Microsoft’s computational services, Cloud and artificial intelligence (AI) will be merged with the drug discovery, development and data science expertise of Novo Nordisk.

September 17, 2022

Bayer’s hunt for a new CEO is on, suggesting Werner Baumann could be headed for an early exit: report

Life sciences

Following years of push-and-pull over the German conglomerate’s top post, Bayer has quietly started a hunt for Baumann’s successor, Bloomberg News reported Tuesday, citing people close to the matter. The new CEO search may portend an early departure for Baumann, whose contract with Bayer isn’t set to expire until April 2024.

September 17, 2022

Bluebird CFO resigns ahead of gene therapy launch

Life sciences

Bluebird bio on Monday said its chief strategy and financial officer, Jason Cole, will leave the company this fall, marking the second time in less than a year the cash-strapped gene therapy developer will replace its top financial executive.